Clinical Trials in Baltimore

Showing 11141-11160 of 20,142 trials

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546

This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.

Acute Respiratory Distress SyndromeCoronavirusHypoxic Respiratory Failure+15 more

PhaseBio Pharmaceuticals Inc.54 participantsStarted Jul 2020

Jacksonville, Florida, United States • Sarasota, Florida, United States • Kansas City, Kansas, United States +1 more locations

TERMINATEDPhase 132 miles

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

NCT01278758

The purpose of this study is to evaluate the safety and pharmacokinetics of ASA404 in patients with refractory or relapsed metastatic cancer with impaired renal function and with normal renal function. It is very possible that patients with renal impairment will show differences in renal excretion of parent ASA404 and its metabolites, warranting a study that leads to a better pharmacokinetic assesssment in this population.

Metastatic Cancer

Novartis Pharmaceuticals7 participantsStarted Mar 2010

Indianapolis, Indiana, United States • Rockville, Maryland, United States • Detroit, Michigan, United States +1 more locations

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Find Trials by Condition in Baltimore

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Development of Serologic Assays for Human Herpes Virus-8

Study of New Software Used During Ablations

Genetics and Pain Severity in Sickle Cell Disease

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Registry Evaluation of a Double Balloon Accessory Device

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

A Phase I Study for Safety and Tolerability of AL002.

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment